CANDESARTAN TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
10-11-2021
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
CANDESARTAN CILEXETIL
Beschikbaar vanaf:
PRO DOC LIMITEE
ATC-code:
C09CA06
INN (Algemene Internationale Benaming):
CANDESARTAN
Dosering:
32MG
farmaceutische vorm:
TABLET
Samenstelling:
CANDESARTAN CILEXETIL 32MG
Toedieningsweg:
ORAL
Eenheden in pakket:
100
Prescription-type:
Prescription
Therapeutisch gebied:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Product samenvatting:
Active ingredient group (AIG) number: 0135220004; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2014-04-14
Productkenmerken
_ _
_Candesartan _
_Page 1 of 35_
PRODUCT MONOGRAPH
PR
CANDESARTAN
Candesartan Cilexetil Tablets
8 mg, 16 mg and 32 mg
Manufacturer's Standard
Angiotensin II AT
1
Receptor Blocker
Pro Doc Ltée
Date of Revision:
2925, boul. Industriel November 10, 2021
Laval, Quebec
H7L 3W9
Submission Control No.: 257568
_ _
_Candesartan _
_Page 2 of 35_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY
PRODUCT
INFORMATION
.................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
4
WARNINGS
AND
PRECAUTIONS
..........................................................................................
4
ADVERSE
REACTIONS
............................................................................................................
8
DRUG
INTERACTIONS
...........................................................................................................
12
DOSAGE
AND
ADMINISTRATION
.......................................................................................
14
OVERDOSAGE
.........................................................................................................................
17
ACTION
AND
CLINICAL
PHARMACOLOGY
.....................................................................
17
STORAGE
AND
STABILITY...................................................................................................
19
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ...................................................... 19
PART II: SCIENTIFIC INFORMATION
................................................................................
21
PHARMACEUTICAL
INFORMATION
..................................................................................
21
CLINICAL
TRIALS
...........................
Lees het volledige document
